Cardioprotective effects of the aminopeptidase P inhibitor apstatin: Studies on ischemia/reperfusion injury in the isolated rat heart

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 4, 1999, Pages 604-611

  Erşahin, Çaǧatay ^a   Euler, David E ^b   Simmons, William H ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b Angeion Corporation   (United States)

Author keywords

Aminopeptidase P; Angiotensin converting enzyme; Apstatin; Bradykinin; Ramiprilat; Ventricular fibrillation

Indexed keywords

AMINOPEPTIDASE P; AMINOPEPTIDASE P INHIBITOR; APSTATIN; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; ICATIBANT; LACTATE DEHYDROGENASE; RAMIPRILAT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME RELEASE; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARRHYTHMIA; BRADYKININ; CARDIOVASCULAR AGENTS; CREATINE KINASE; DRUG INTERACTIONS; L-LACTATE DEHYDROGENASE; MALE; PEPTIDES; PERFUSION; PROTEASE INHIBITORS; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; VENTRICULAR FIBRILLATION;

EID: 0032832870     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199910000-00019     Document Type: Article

References (67)

1. Baumgarten CR, Linz W, Kunkel G, Schölkens BA, Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 1993;108:293-5.
2. Noda K, Sasaguri M, Ideishe M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res 1993;27:334-40.
3. Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli AG. A local kallikrein-kinin system is present in rat hearts. Hypertension 1994; 23:919-23.
4. Linz W, Wiemer G, Schölkens BA. Role of kinins in the pathophysiology of myocardial ischemia: in vitro and in vivo studies. Diabetes 1996;45(suppl 1):551-8.
5. Parratt JR, Vegh A, Zeitlin J, et al. Bradykinin and endothelial-cardiac myocyte interactions in ischemic preconditioning. Am J Cardiol 1997;80:124A-31A.
6. Erşahin Ç, Simmons WH. Inhibition of both aminopeptidase P and angiotensin converting-enzyme prevents bradykinin degradation in the rat coronary circulation. J Cardiovasc Pharmacol 1997;30:96-101.
7. Linz W, Wiemer G, Schölkens BA. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol 1992;24:909-19.
8. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contributions of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.
9. Liu Y-H, Yang X-P, Sharow VG, Sigmon DH, Sabbah HN, Carretero OA. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/ reperfusion injury in rats. Hypertension 1996;27:7-13.
10. Shimada Y, Avkiran M. Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting enzyme/kininase II in the ischemic zone: mediated by endogenous bradykinin? J Cardiovasc Pharmacol 1996;27:428-38.
11. Prechel MM, Orawski AT, Maggiora LL, Simmons WH. Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. J Pharmacol Exp Ther 1995;275:1136-42.
12. Kitamura S-I, Carbini LA, Carretero OA, Simmons WH, Scicli AG. Potentiation by [an] aminopeptidase P [inhibitor] of [the] blood pressure response to bradykinin. Br J Pharmacol 1995;114: 6-7.
13. Kitamura S-I, Carbini LA, Carretero OA, Simmons WH, Scicli AG. Effect of combined inhibition of angiotensin-converting enzyme and aminopeptidase P on hemodynamic response in severe hypertension. Hypertension 1995;26:554.
14. Erşahin Ç, Simmons WH. Cardioprotective effects of the amino-peptidase P inhibitor, apstatin. FASEB J 1998;12:A409.
15. Döring HJ, Dehnart H. The isolated perfused heart according to Langendorff. 1st English ed. March, Germany: Biomesstechnik-Verlag, 1988:25-31.
16. Apstein CS, Mueller M, Hood WB. Ventricular contracture and compliance changes with global ischemia and reperfusion, and their effect on coronary resistance in the rat. Circ Res 1977;41: 206-17.
17. Walker MJA, Curtis MJ, Hearse DJ, et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res 1988;22:447-55.
18. Orawski AT, Simmons WH. Purification and properties of membrane-bound aminopeptidase P from rat lung. Biochemistry 1995; 34:11227-36.
19. Dendorfer A, Wolfram S, Wellhöner P, Korsman K, Dominiak P. Intravascular and interstitial degradation of bradykinin in isolated perfused rat heart. Br J Pharmacol 1997;122:1179-87.
20. Ambrosio G, Weisfeldt ML, Jacobus WE, Flaherty JT. Evidence for a reversible oxygen radical-mediated component of reperfusion injury: reduction by recombinant human superoxide dismutase administered at the time of reflow. Circulation 1987;75:282-91.
21. Linz W, Martorana PA, Schölkens BA. Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol 1990;15:S99-109.
22. Minshall RD, Vogel SM, Rabito SF. Are the inotropic and antiarrhythmic effects of bradykinin due to increases in coronary flow? Am J Cardiol 1997;80:148A-52A.
23. Ryan JW, Carlin G, Berryer P, Chung A. Potentiation of bradykinin by inhibitors of angiotensin converting enzyme. In: Fritz H, Back N, Dietze G, Haberland GL, eds. Kinins III (Part A). New York: Plenum Press, 1983:613-20.
24. (Advances in Experimental Medicine and Biology, Vol 156A).
25. Piedimonte G, Nadel JA, Long CS, Hoffman JIE. Neutral endopeptidase in the heart: neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation. Circ Res 1994;75:770-9.
26. Maxwell AJ, Husseini WK, Piedimonte G, Hoffman JIE. Effects of inhibiting neutral endopeptidase and kininase II on coronary and systemic hemodynamics in rats. Am J Physiol 1995;269:H1016-29.
27. Gräfe M, Auch-Schwelk W, Graf K, et al. Isolation and characterization of macrovascular and microvascular endothelial cells from human hearts. Am J Physiol 1994;267:H2138-48.
28. Schriefer JA, Broudy EP, Hassen AH. Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model. J Pharmacol Exp Ther 1996;278:1034-9.
29. Yang X-P, Liu Y-H, Peterson E, Carretero OA. Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/ reperfusion injury: the role of kinins. J Cardiovasc Phannacol 1997;29:250-6.
30. Zhang X, Nasjletti A, Xu X, Hintze TH. Neutral endopeptidase and angiotensin-converting enzyme inhibitors increase nitric oxide production in isolated canine coronary microvessels by a kinin-dependent mechanism. J Cardiovasc Phannacol 1998;31:623-9.
31. Dumoulin M-J, Adam A, Blais C Jr, Lamontagne D. Metabolism of bradykinin by the rat coronary vascular bed. Cardiovasc Res 1998;38:229-36.
32. Erdös EG, Skidgel RA. Metabolism of bradykinin by peptidases in health and disease. In: Farmer SG, ed. The kinin system. New York: Academic Press, 1997:111-41.
33. Baker CRF Jr, Little AD, Little GH, Canizaro PC, Behal FJ. Kinin metabolism in the perfused ventilated rat lung: bradykinin metabolism in a system modeling the normal, uninjured lung. Circ Shock 1991;33:37-47.
34. Pesquero JB, Jubilut GN, Lindsey CJ, Paiva ACM. Bradykinin metabolism pathway in the rat pulmonary circulation. J Hypertens 1992;10:1471-8.
35. Ryan JW, Berryer P, Chung AYK, Sheffy DH. Characterization of rat pulmonary vascular aminopeptidase P in vivo: role in the inactivation of bradykinin. J Pharmacol Exp Ther 1994;269:941-7.
36. Altstein M, Bachar E, Vogel Z, Blumberg S. Protection of enkephalins from enzymatic degradation utilizing selective metal-chelating inhibitors. Eur J Pharmacol 1983;91:353-61.
37. Orlowski M, Wilk S. Purification and specificity of a membrane-bound metalloendopeptidase from bovine pituitaries. Biochemistry 1981;20:4942-50.
38. Chatelein RE, Ghai RD, Trapani AJ, et al. Antihypertensive and natriuretic effects of CGS 30440: a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther 1998;284:974-82.
39. Parratt JR, Vegh A, Papp JG. Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning: a brief review of the evidence. Can J Physiol Pharmacol 1995;73:837-42.
40. Wiemer G, Schölkens BA, Linz W. Endothelial protection by converting enzyme inhibitors. Cardiovasc Res 1994;28:166-72.
41. Wiemer G, Schölkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autocoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-63.
42. Hartman JC. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg 1995;60: 789-92.
43. Falkenhahn M, Franke F, Bohle RM, et al. Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension 1995;25:219-26.
44. Graf K, Koehne P, Gräfe M, Zhang M, Auch-Schwelk W, Fleck E. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension 1995;26:230-5.
45. Schaper J, Scholz D, Devaux B, et al. The morphology and structure of the coronary microvasculature. In: Haunsø S, Aldershvile J, Svendsen JH, eds. Coronary microcirculation during ischaemia and reperfusion. Copenhagen: Munksgaard, 1997:17-29.
46. Ryan JW, Papapetropoulos A, Ju H, et al. Aminopeptidase P is disposed on human endothelial cells. Immunopharmacology 1996; 32:149-52.
47. Venema RC, Ju H, Zou R, Venema VJ, Ryan JW. Cloning and tissue distribution of human membrane-bound aminopeptidase P. Biochim Biophys Acta 1997;1354:45-8.
48. 1 receptor. Br J Pharmacol 1993;108:318-22.
49. Paulus WJ. Endothelial control of vascular and myocardial function in heart failure. Cardiovasc Drugs Ther 1994;8:437-46.
50. Brew EC, Mitchell MB, Rehring TF, et al. Role of bradykinin in cardiac functional protection after global ischemia-reperfusion in rat heart. Am J Physiol 1995;38:H1370-8.
51. Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995;77:611-21.
52. Bugge E, Ytrehus K. Bradykinin protects against infarction but does not mediate ischemic preconditioning in the isolated rat heart. J Mol Cell Cardiol 1996;28:2333-41.
53. Shah AM. Paracrine modulation of heart cell function by endothelial cells. Cardiovasc Res 1996;31:847-67.
54. Brunner F, Kukovetz WR. Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors: role of suppression of endogenous endothelin secretion. Circulation 1996;94:1752-61.
55. Siegried MR, Erhardt J, Rider T, Ma X-L, Lefer AM. Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. J Pharmacol Exp Ther 1992;260:668-75.
56. Weyrich AS, Ma X-L, Lefer AM. The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation 1992;86:279-88.
57. Parratt J. Endogenous myocardial protective (antiarrhythmic) substances. Cardiovasc Res 1993;27:693-702.
58. 2+ in intact cardiac myocytes. Circ Res 1994;74:970-8.
59. Vuorinen P, Laustiola K, Metsä-Ketelä T. The effects of cyclic AMP and cyclic GMP on redox state and energy state in hypoxic rat atria. Life Sci 1984;35:155-61.
60. Momose N, Fukuo K, Mormoto S, Ogihara T. Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin. Hypertension 1993;21:921-4.
61. 2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ Res 1995;76:773-80.
62. Clerk A, Gillespie-Brown J, Fuller SJ, Sugden PH. Stimulation of phosphatidylinositol hydrolysis, protein kinase C translocation, and mitogen-activated protein kinase activity by bradykinin in rat ventricular myocytes: dissociation from the hypertrophic response. Biochem J 1996;317:109-18.
63. Busse R, Fleming I. Molecular responses of endothelial tissue to kinins. Diabetes 1996;45(suppl 1):S2-13.
64. Drexler H. Endothelial factors. In: Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS, eds. Heart failure: scientific principles and clinical practice. New York: Churchill Livingstone, 1997:173-86.
65. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997;77:1165-232.
66. Kloner RA, Bolli R, Marban E, Reinlib L, Braunwald E, and participants. Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. Circulation 1998;97:1848-67.
67. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-33.